IRIDEX (NASDAQ:IRIX) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of IRIDEX (NASDAQ:IRIX) in a research note issued to investors on Friday. The brokerage set a “hold” rating on the medical equipment provider’s stock.

IRIDEX Stock Down 4.0 %

IRIX opened at $1.67 on Friday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.85 and a current ratio of 1.54. The company has a market cap of $27.78 million, a price-to-earnings ratio of -2.49 and a beta of 0.81. IRIDEX has a one year low of $1.27 and a one year high of $3.65. The business’s fifty day moving average is $1.66 and its two-hundred day moving average is $1.84.

IRIDEX (NASDAQ:IRIX) last released its quarterly earnings data on Tuesday, November 12th. The medical equipment provider reported ($0.12) EPS for the quarter. The business had revenue of $11.58 million during the quarter. IRIDEX had a negative return on equity of 192.95% and a negative net margin of 22.79%. During the same quarter in the previous year, the company earned ($0.11) EPS.

About IRIDEX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.